newsfilter
← Latest News
Earnings Call Transcripts·

UBS Global Biopharma Conference - BIOAGE LABS INC

  • Explicit Guidance:

    • Clinical Readouts: Targeting Phase 2 data release for BGE-102 (NLRP3 inhibitor) in obese/inflamed cohorts by the end of the current year; targeting BGE-102 data release for the DME (Quell DME) proof-of-concept trial in the second half of next year.
    • Regulatory Filings: Guiding to IND filing for the first APJ agonist program by the end of the current year.
    • Financial Runway: Cash position of slightly over $350 million is projected to fund operations through 2029, covering NLRP3 assets to late-phase (Quell DME/QUAL-CV), APJ programs to proof-of-concept, and an additional undisclosed NLRP3 indication.
  • Business-Segment Outlook:

    • NLRP3 (BGE-102) Strategy: Shifting near-term focus from ASCVD outcomes trials to ophthalmology (DME) as a beachhead, with plans to expand into uveitic macular edema and geographic atrophy (GA) pending DME readout.
    • Indication Expansion: Planning to add an additional, as-yet-undisclosed indication to the NLRP3 portfolio to align with upstream biology (IL-1β/IL-18 inhibition) and de-risked endpoints.
    • APJ Agonists: Developing both oral and parenteral versions; preclinical data suggests potential to double weight loss and restore body composition when combined with appetite-suppressing mechanisms.
    • Platform Licensing: Advancing therapeutic antibodies with Eli Lilly (novel targets identified via aging platform) and target discovery with Novartis (focusing on exercise mimicry and longevity).
  • Market and Competitive Outlook:

    • NLRP3 Landscape: Differentiation via novel binding site (non-ATPase pocket) enabling deeper inhibition (98% trough IL-1β suppression) and inflammasome disassembly compared to derivatives targeting the same site.
    • Cardiovascular Context: Zeus trial (IL-6 inhibitor) failure viewed as validating upstream NLRP3 targeting rather than dismissing the biology; positioning BGE-102 to capture incremental efficacy by inhibiting IL-1β, IL-18, and pyroptosis.
    • Competitive Dynamics: Ready to pivot back to ASCVD outcomes trials if competitor programs (e.g., Lilly's NLRP3 program or Artemis trial results) demonstrate definitive signals or catalyze investor appetite for outcomes studies.
    • Ophthalmology Value Proposition: Targeting the 40% of DME patients in "watch and wait" categories resistant to intravitreal therapy, as well as VEGF-incomplete responders, via an oral, well-tolerated modality.
  • Macro / Industry Outlook:

    • Biology Validation: Zeus trial results interpreted as confirming IL-6 is likely too downstream (a biomarker rather than causal), reinforcing the strategic pivot to upstream NLRP3 inhibition.
    • Clinical Design: Anticipating potential for "surprisingly definitive signals" from ongoing acute MI trials (Artemis) in the first half of next year which could alter the NLRP3 cardiovascular roadmap.
    • Safety Profile: Confidence in the novel APJ chemotype eliminating the idiosyncratic liver safety signal observed in prior Amgen-licensed assets, driven by a distinct chemical structure and optimized low-dose profile (<100 mg QD).
  • Strategic Initiatives:

    • Portfolio Prioritization: Double down on DME to establish PK/PD relationships in the eye and serve as an entry point for broader ophthalmology strategy.
    • Asset Development: Advancing BGE-102 in Phase 2 to determine dose-response relationships for IL-1β suppression and downstream metabolic markers (CRP, IL-6, fibrinogen) and liver imaging (MRI).
    • Partnership Execution: Leveraging 50-year human aging cohorts with biobanks to identify targets predictive of longevity and physical function; executing early-stage R&D collaborations with Lilly (antibodies) and Novartis (target discovery).
  • Risks and Headwinds to Outlook:

    • Capital Constraints: While $350M runway extends to 2029, management acknowledges the high capital cost of five-year, half-a-billion-dollar outcomes trials, noting that investor appetite for such trials has diminished post-Zeus.
    • Clinical Uncertainty: DME readout timing (H2 next year) and outcomes are subject to trial results; success in DME is a prerequisite for entering GA/other indications.
    • Competitive Trigger Dependency: Future ASCVD development is contingent on external "de-risking signals" from competitors (e.g., Lilly, Artemis) rather than internal execution in the near term.
    • Safety Risks: While mitigated, the risk of idiosyncratic liver injury remains a historical concern for APJ agonists, though management believes the new chemotype and lower dosing address this.
  • Management Tone on the Future:

    • Confidence: High confidence in the distinct biological differentiation of BGE-102 (98% trough inhibition) and the strategic logic of pivoting to ophthalmology where the company can control trial scale and endpoint selection.
    • Hedging: Explicitly states that the move away from ASCVD is "not a move away" but a timing shift; retains readiness to "jump right back in" if competitor data or the Artemis trial yields definitive positive signals.
    • Caveats: Acknowledges the market's reduced appetite for late-stage outcomes trials following the Zeus failure, necessitating a focus on earlier proof-of-concept and smaller trial scales to generate value.
  • Miscellaneous:

    • Differentiation: BGE-102 uniquely achieves near-complete 24-hour target inhibition and tissue distribution (CNS, retina) superior to historical NLRP3 programs.
    • Trial Design: DME trial (Quell DME) powered for a 4-letter improvement in BCVA, comparing monotherapy and combination with VEGF, aiming to replicate IL-6 trial designs that showed separation by two months.
    • Market Gap: Emphasizes patient resistance to monthly/quarterly intravitreal injections as a key market driver for an oral NLRP3 inhibitor in DME.
Company
BIOAGE LABS INC
Keywords
BIOAGE LABS INC